Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Immune Landscape Associated with Response to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Relapsed/Refractory Hodgkin Lymphoma (E4412 Phase 1)

Blood (2023) 142 (Supplement 1): 4382.

https://doi.org/10.1182/blood-2023-174903

Published: 2023

Journal Articles

Natural killer cell memory precedes HLH in monozygotic twins discordant for chronic active Epstein-Barr virus disease

Blood (2023) 141 (17): 2151–2155.

https://doi.org/10.1182/blood.2022018309

Published: 2023

Includes: Supplemental data

Journal Articles

Developing CD70-Targeted CAR-T Cells for the Treatment of Hematological and Solid Malignancies

Yuan Lu, Hui Huang, Cheng Chen, Hui Wang, Huilin Wu, Xiaoqin Liu, Wei Zhao, Chunyan Gao, Siyuan Tan

Blood (2022) 140 (Supplement 1): 12695.

https://doi.org/10.1182/blood-2022-160106

Published: 2022

Journal Articles

Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma

Hong-Hui Huang, PhD MD, Jian Hou, PhD MD, Yang-Ming Zhang, PhD, Yu-Bo Zhou, PhD, Li Jia, PhD, Fa-Jun Nan, PhD

Blood (2019) 134 (Supplement_1): 5591.

https://doi.org/10.1182/blood-2019-129683

Published: 2019

Journal Articles

Somatic Mutations of Epigenetic Regulator Genes in Diffuse Large B-Cell Lymphoma

Yao-hui Huang, Weili Zhao, MD PhD

Blood (2016) 128 (22): 1756.

https://doi.org/10.1182/blood.V128.22.1756.1756

Published: 2016

Journal Articles

A Meta-Analysis and Meta-Regression of the Efficacy of Front-Line Treatment Combinations with Ponatinib Versus 1st- and 2nd-Generation Tyrosine Kinase Inhibitors for Ph+ Acute Lymphoblastic Leukemia

Elias J. Jabbour, MD, Maral DerSarkissian, PhD, Mei Sheng Duh, Nora McCormick, MSc, Wendy Y. Cheng, MPH, MPhil, Lisa J. McGarry, MPH, Ariadne Souroutzidis, BA, Hui Huang, PhD MBA, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 5189.

https://doi.org/10.1182/blood.V128.22.5189.5189

Published: 2016

Journal Articles

Predictors of Ponatinib Therapy Duration Among Real-World Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients in the US

Michael J. Mauro, MD, Lisa J. McGarry, MPH, Stephanie Lustgarten, PhD, Hui Huang, PhD MBA

Blood (2016) 128 (22): 3081.

https://doi.org/10.1182/blood.V128.22.3081.3081

Published: 2016

Journal Articles

RUNX1 Is a Candidate Transcriptional Effector in Juvenile Myelomonocytic Leukemia

Elisa Dorantes Acosta, MD PhD, Hui Huang, PhD, Sara P. Garcia, PhD, Elliot Stieglitz, MD, Mignon L. Loh, MD, G C Yuan, Alan B. Cantor

Blood (2016) 128 (22): 2699.

https://doi.org/10.1182/blood.V128.22.2699.2699

Published: 2016

Journal Articles

Real-World Ponatinib Prescribing Patterns and Outcomes in US Patients

Michael J. Mauro, MD, Lisa J. McGarry, MPH, Mo Yang, PhD, Stephanie Lustgarten, PhD, Hui Huang, MBA, PhD

Blood (2015) 126 (23): 1591.

https://doi.org/10.1182/blood.V126.23.1591.1591

Published: 2015

Journal Articles

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Franck E. Nicolini, MD PhD, Grzegorz W. Basak, MD PhD, Dong-Wook Kim, MD PhD, Eduardo Olavarria, MD PhD, Javier Pinilla-Ibarz, MD PhD, Jane F. Apperley, MD, Timothy P. Hughes, MD, Dietger Niederwieser, MD, Michael J. Mauro, MD, Charles Chuah, MD PhD, Andreas Hochhaus, MD, Giovanni Martinelli, MD PhD, Maral DerSarkissian, PhD, Andrew Kageleiry, BS, Mo Yang, PhD, Hui Huang, MBA, PhD, Lisa J. McGarry, MPH, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 480.

https://doi.org/10.1182/blood.V126.23.480.480

Published: 2015

Journal Articles

Comparative Efficacy Among 3 rd Line Post-Imatinib Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients after Failure of Dasatinib or Nilotinib Tyrosine Kinase Inhibitors

Jeffrey H. Lipton, MD PhD, Dhvani Shah, MS, Vanita Tongbram, MBBS, MPH, Manpreet K Sidhu, BA, PhD MBA, Hui Huang, PhD MBA, Lisa J McGarry, MPH, Stephanie Lustgarten, PhD, Neil Hawkins, PhD

Blood (2014) 124 (21): 4551.

https://doi.org/10.1182/blood.V124.21.4551.4551

Published: 2014

Journal Articles

Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison

Moshe Yair Levy, MD, Lisa J McGarry, MPH, Hui Huang, PhD MBA, Stephanie Lustgarten, PhD, Christopher Nieset, PharmD, Frank G Haluska

Blood (2014) 124 (21): 3154.

https://doi.org/10.1182/blood.V124.21.3154.3154

Published: 2014

Journal Articles

Real-World Prescribing Patterns with Ponatinib Among New and Ongoing US Patients

Lisa J McGarry, MPH, Greg Wolfe, PharmD, Ann Steagall, BSN, RN, OCN, Hui Huang, PhD MBA

Blood (2014) 124 (21): 5521.

https://doi.org/10.1182/blood.V124.21.5521.5521

Published: 2014

Journal Articles

Cause of Death in Resistant and Advanced Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs).

Lisa J McGarry, MPH, Chakkarin Burudpakdee, PharmD, Smeet Gala, MS, Arpamas Seetasith, PhD, Merena Nanavaty, MS, Hui Huang, PhD MBA

Blood (2014) 124 (21): 5524.

https://doi.org/10.1182/blood.V124.21.5524.5524

Published: 2014

Journal Articles

Comparative Efficacy Among Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients After Failure Of 2 nd Generation Tyrosine Kinase Inhibitors (2G TKIs)

Jeff H. Lipton, PhD, MD, Peter Bryden, MSc, BSc, Manpreet K Sidhu, BA, PhD, MBA, Hui Huang, PhD, MBA, Lisa J McGarry, BA, MPH, ABD DSc, Stephanie Lustgarten, PhD, Beth Woods, MSc, BA, Neil Hawkins, PhD

Blood (2013) 122 (21): 4010.

https://doi.org/10.1182/blood.V122.21.4010.4010

Published: 2013

Journal Articles

Clonal Leukemic Evolution In Myelodysplastic Syndromes With ASXL1 and EZH2 mutations: A Comparative Analysis Of 58 Paired Samples

Hsuan-Jen Shih, MD, Lee-Yung Shih, MD, Hung Chang, MD, Ming-Chung Kuo, MD, Tung-Huei Lin, MS, Chen-Yu Lai, MS, Yu-Shu Shih, MS, Yu-Hui Huang, MS, Tung-Liang Lin, MD, Po-Nan Wang, MD, Jin-Hou Wu, MD

Blood (2013) 122 (21): 2786.

https://doi.org/10.1182/blood.V122.21.2786.2786

Published: 2013

Journal Articles

Mutations Of Genes Regulating DNA Methylation Are Common In MLL Partial Tandem Duplication AML and DNMT3A Mutations Are Associated With Adverse Outcome

Hsiao-Wen Kao, MD, Lee-Yung Shih, MD, Ming-Chung Kuo, MD, Tung-Liang Lin, MD, Sung-Tzu Liang, PhD, Chao-Ping Yang, MD, Yu-Shu Shih, MS, Yu-Hui Huang, MS, Tung-Huei Lin, MS, Der-Cherng Liang, MD

Blood (2013) 122 (21): 1407.

https://doi.org/10.1182/blood.V122.21.1407.1407

Published: 2013

Journal Articles

Potential Role Of RUNX1 In The Pathogenesis Of Juvenile Myelomonocytic Leukemia (JMML)

Hui Huang, PhD, Daniel E. Bauer, MD, PhD, Mignon L. Loh, MD, Govind Bhagat, MD, Alan B. Cantor, M.D., Ph.D., Andrew L. Kung, MD, PhD

Blood (2013) 122 (21): 45.

https://doi.org/10.1182/blood.V122.21.45.45

Published: 2013

Journal Articles

Src Kinase Can Activate RUNX1 Activity Via Phosphorylation Of C-Terminal Tyrosines and Activated RUNX1 Stimulates Granulopoiesis

Alan D. Friedman, M.D., Wan Yee Leong, M.Sc., Hong Guo, M.D., Ph.D., Ou Ma, Ph.D., Alan B. Cantor, M.D., Ph.D., Hui Huang, Ph.D.

Blood (2013) 122 (21): 1210.

https://doi.org/10.1182/blood.V122.21.1210.1210

Published: 2013

Journal Articles

Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1 , TET2 , IDH1 , IDH2 , and DNMT3A

Der-Cherng Liang, Hsi-Che Liu, Chao-Ping Yang, Tang-Her Jaing, Iou-Jih Hung, Ting-Chi Yeh, Shih-Hsiang Chen, Jen-Yin Hou, Ying-Jung Huang, Yu-Shu Shih, Yu-Hui Huang, Tung-Huei Lin, Lee-Yung Shih

Blood (2013) 121 (15): 2988–2995.

https://doi.org/10.1182/blood-2012-06-436782

Published: 2013

Includes: Supplemental data

NARROW

Immune Landscape Associated with Response to Brentuximab Vedotin with Ipilimumab and/or Nivolumab in Relapsed/Refractory Hodgkin Lymphoma (E4412 Phase 1)

Natural killer cell memory precedes HLH in monozygotic twins discordant for chronic active Epstein-Barr virus disease

Developing CD70-Targeted CAR-T Cells for the Treatment of Hematological and Solid Malignancies

Phase 1 Study of Bisthianostat, an Orally Efficacious Pan-HDAC Inhibitor: Part Results of Safety, Pharmacokinetics and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma

Somatic Mutations of Epigenetic Regulator Genes in Diffuse Large B-Cell Lymphoma

A Meta-Analysis and Meta-Regression of the Efficacy of Front-Line Treatment Combinations with Ponatinib Versus 1st- and 2nd-Generation Tyrosine Kinase Inhibitors for Ph+ Acute Lymphoblastic Leukemia

Predictors of Ponatinib Therapy Duration Among Real-World Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients in the US

RUNX1 Is a Candidate Transcriptional Effector in Juvenile Myelomonocytic Leukemia

Real-World Ponatinib Prescribing Patterns and Outcomes in US Patients

The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation

Comparative Efficacy Among 3 rd Line Post-Imatinib Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients after Failure of Dasatinib or Nilotinib Tyrosine Kinase Inhibitors

Benefit-Risk of Ponatinib Vs. Bosutinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Failed Two Prior Tyrosine Kinase Inhibitors (TKIs): An Indirect Comparison

Real-World Prescribing Patterns with Ponatinib Among New and Ongoing US Patients

Cause of Death in Resistant and Advanced Chronic Myeloid Leukemia (CML) Patients Treated with Tyrosine Kinase Inhibitors (TKIs).

Comparative Efficacy Among Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients After Failure Of 2 nd Generation Tyrosine Kinase Inhibitors (2G TKIs)

Clonal Leukemic Evolution In Myelodysplastic Syndromes With ASXL1 and EZH2 mutations: A Comparative Analysis Of 58 Paired Samples

Mutations Of Genes Regulating DNA Methylation Are Common In MLL Partial Tandem Duplication AML and DNMT3A Mutations Are Associated With Adverse Outcome

Potential Role Of RUNX1 In The Pathogenesis Of Juvenile Myelomonocytic Leukemia (JMML)

Src Kinase Can Activate RUNX1 Activity Via Phosphorylation Of C-Terminal Tyrosines and Activated RUNX1 Stimulates Granulopoiesis

Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1 , TET2 , IDH1 , IDH2 , and DNMT3A

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only